Terence Flynn
Stock Analyst at Morgan Stanley
(4.23)
# 390
Out of 5,182 analysts
248
Total ratings
57.25%
Success rate
12.59%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $596 → $612 | $441.20 | +38.71% | 5 | Apr 10, 2026 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $471 → $519 | $588.38 | -11.79% | 12 | Apr 10, 2026 | |
| RPRX Royalty Pharma | Maintains: Overweight | $61 → $63 | $50.00 | +26.00% | 14 | Apr 10, 2026 | |
| PFE Pfizer | Maintains: Equal-Weight | $27 → $28 | $27.56 | +1.60% | 22 | Apr 10, 2026 | |
| JNJ Johnson & Johnson | Maintains: Overweight | $262 → $267 | $234.18 | +14.01% | 29 | Apr 10, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,313 → $1,327 | $927.03 | +43.15% | 25 | Apr 10, 2026 | |
| BNTX BioNTech SE | Maintains: Overweight | $125 → $126 | $102.92 | +22.43% | 7 | Apr 10, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $309 → $326 | $355.30 | -8.25% | 13 | Apr 10, 2026 | |
| ALMS Alumis | Maintains: Overweight | $33 → $38 | $24.99 | +52.06% | 4 | Mar 20, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $269 → $270 | $208.38 | +29.57% | 20 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $23 → $20 | $24.25 | -17.53% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $36 | $17.51 | +105.60% | 7 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $21 | $10.98 | +91.26% | 5 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $37 | $60.17 | -38.51% | 12 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $102 | $119.07 | -14.34% | 20 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $50.75 | +146.31% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $9.76 | -7.79% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $11.00 | - | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $57.99 | -44.82% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $14.95 | -26.42% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.92 | +173.97% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $177.35 | +145.84% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $309.66 | - | 2 | Oct 2, 2017 |
Vertex Pharmaceuticals
Apr 10, 2026
Maintains: Overweight
Price Target: $596 → $612
Current: $441.20
Upside: +38.71%
United Therapeutics
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $471 → $519
Current: $588.38
Upside: -11.79%
Royalty Pharma
Apr 10, 2026
Maintains: Overweight
Price Target: $61 → $63
Current: $50.00
Upside: +26.00%
Pfizer
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $27 → $28
Current: $27.56
Upside: +1.60%
Johnson & Johnson
Apr 10, 2026
Maintains: Overweight
Price Target: $262 → $267
Current: $234.18
Upside: +14.01%
Eli Lilly and Company
Apr 10, 2026
Maintains: Overweight
Price Target: $1,313 → $1,327
Current: $927.03
Upside: +43.15%
BioNTech SE
Apr 10, 2026
Maintains: Overweight
Price Target: $125 → $126
Current: $102.92
Upside: +22.43%
Amgen
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $309 → $326
Current: $355.30
Upside: -8.25%
Alumis
Mar 20, 2026
Maintains: Overweight
Price Target: $33 → $38
Current: $24.99
Upside: +52.06%
AbbVie
Feb 5, 2026
Maintains: Overweight
Price Target: $269 → $270
Current: $208.38
Upside: +29.57%
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $24.25
Upside: -17.53%
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $17.51
Upside: +105.60%
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $10.98
Upside: +91.26%
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $60.17
Upside: -38.51%
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $119.07
Upside: -14.34%
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $50.75
Upside: +146.31%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $9.76
Upside: -7.79%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $11.00
Upside: -
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $57.99
Upside: -44.82%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $14.95
Upside: -26.42%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.92
Upside: +173.97%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $177.35
Upside: +145.84%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $309.66
Upside: -